Fan Xiaoying, Zhang Yao
Department of Cardiology, Second Affiliated Hospital of Harbin Medical University, Xuefu Road, Harbin, People's Republic of China.
Pak J Pharm Sci. 2016 Sep;29(5 Suppl):1769-1773.
The aim of this study was to evaluate the safety and efficacy of triple antithrombotic therapy with warfarin, aspirin and clopidogrel in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI). We retrospectively reviewed clinical and follow-up data of 156 consecutive patients with atrial fibrillation after percutaneous coronary stenting. Patients were followed up at 2 and 12 months. A total of 156 consecutive patients were identified. There were 70 patients (dual antiplatelet therapy group, DAPT), warfarin was not used and 86 patients (triple antithrombotic therapy group, TT), both dual antiplatelet therapy and warfarin therapy were prescribed. The baseline data and PCI data were similar in the two groups. The outcome events were similar in the two groups except for bleeding events. There was a significant difference in bleeding risk in the two groups. In summary, triple antithrombotic therapy increases the bleeding risk. Dual antiplatelet therapy decreased this bleeding risk but tended to increase the risk of stroke.
本研究的目的是评估华法林、阿司匹林和氯吡格雷三联抗栓治疗在接受经皮冠状动脉介入治疗（PCI）的房颤患者中的安全性和有效性。我们回顾性分析了156例经皮冠状动脉支架置入术后连续房颤患者的临床和随访数据。患者在2个月和12个月时进行随访。共确定了156例连续患者。其中70例患者（双联抗血小板治疗组，DAPT）未使用华法林，86例患者（三联抗栓治疗组，TT）同时接受双联抗血小板治疗和华法林治疗。两组的基线数据和PCI数据相似。除出血事件外，两组的结局事件相似。两组的出血风险存在显著差异。总之，三联抗栓治疗增加了出血风险。双联抗血小板治疗降低了这种出血风险，但倾向于增加中风风险。
